NNVC News Saturday, July 12, 2014 2:23:54 PM $NNVC
Post# of 175
Posted On: 07/12/2014 2:24:21 PM
NNVC News Saturday, July 12, 2014 2:23:54 PM $NNVC
NanoViricides Reports that its Director Dr. Milton Boniuk, a Director, Has Invested $5M into the Company in a Convertible Debenture
Business Wire - Wed Jul 02, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"
reported today that Milton Boniuk, MD, the Caroline F. Elles Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company, has invested $5M in the Company in the form of a convertible debenture (the "Debenture" .
NanoViricides Down 5.4%, Shares Slide into the Red (NNVC)
Comtex SmarTrend(R) - Tue Jul 01, 12:44PM CDT
NanoViricides (NASDAQ:NNVC) is one of today's worst performing low-priced stocks, down 5.4% to $4.00 on 1.0x average daily volume. NanoViricides has traded 262,000 shares thus far today, vs. average volume of 256,000 shares per day. The stock has underperformed the Dow (-5.4% to the Dow's 1.0%) and underperformed the S&P 500 (-5.4% to the S&P's 0.9%) during today's trading.
Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fp7wfj/herpes_labialis) has announced the addition of the "Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beech Tree Labs, Inc. - BioAlliance Pharma SA - Foamix Ltd. - NanoBio Corporation - NanoViricides, Inc. - Redox Pharmaceutical Corporation For more information visit http://www.researchandmarkets.com/research/fp...s_labialis
NanoViricides Reports That a Certificate of Occupancy Has Been Issued for the New cGMP Manufacturing and R&D Facility in Shelton, CT
Business Wire - Wed Jun 25, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" reports that the Construction Phase for its total renovation program of the facility at 1 Controls Drive, Shelton, CT is now complete. The City of Shelton has issued a Certificate of Occupancy for this facility after inspection of the new facility. NanoViricides is now performing specific modifications for its custom equipment and utilities needs. Simultaneously, the facility validation process has also been started. The Company is in negotiations to purchase this facility rather than to lease it.
NanoViricides President Dr. Diwan to Present at the Wall Street Analyst Forum Today, June 19th, in New York City
Business Wire - Thu Jun 19, 7:30AM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" reports that its President, Dr. Anil Diwan, will be presenting at the Wall Street Analyst Forum's 25th Annual Institutional Investor Conference today at 11:20am Eastern Time at the University Club in New York City. The event is being webcast. To participate, the registration link is http://www.visualwebcaster.com/event.asp?id=99581. Investors interested in attending the presentation in person may register at: www.analyst-conference.com/investor-registration.
NanoViricides, Inc. Reports That NNVC is in the Preliminary Additions List of The Russell Global, The Russell 3000, The Russell 2000 and the Russell Microcap Indexes
Business Wire - Mon Jun 16, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" , reports that NanoViricides, Inc. is in the preliminary list for addition to the Russell Global, Russell 3000, Russell 2000, and Russell Microcap Indexes when Russell Investments ("Russell" reconstitutes its U.S. and global equity indexes on June 27, 2014. The preliminary additions and deletions for the Russell Global, Russell 3000(R) and Russell Microcap(R) Indexes were listed on the Russell website on Friday, June 13, 2014, after the U.S. stock market closed (http://www.russell.com/indexes/americas/tools-resources/reconstitution/additions-deletions.page). Russell will provide further updates on Friday, June 20 and 27. The newly reconstituted Russell indexes will take effect after the US stock market close on Friday, June 27.
Coronavirus Infection - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3fg3jv/coronavirus) has announced the addition of the "Coronavirus Infection - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronavirus Infection and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Novavax, Inc. - NanoViricides, Inc. - Synairgen plc For more information visit http://www.researchandmarkets.com/research/3f...oronavirus
NanoViricides CEO Dr. Seymour to Present at the LD Micro Invitational Conference Today, June 4th
Business Wire - Wed Jun 04, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" reports that its CEO, Dr. Eugene Seymour, MD, MPH, will be presenting at the LD Micro Invitational Conference today at 5pm Pacific Time at the Luxe Sunset Boulevard Hotel in West Los Angeles.
SeeThruEquity 3rd Annual Microcap Investor Conference To Be Held May 28, 2014
ACCESSWIRE - Thu May 22, 8:11AM CDT
Conference Being Held at Convene Grand Central in Midtown
NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Clinical Trials of its First Two Drug Candidates
Business Wire - Mon May 19, 6:01AM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" , has filed its quarterly report with the Securities and Exchange Commission on Thursday, May 15th, in a timely fashion. The submission can be downloaded from the SEC website at http://www.sec.gov/Archives/edgar/data/137900...44_10q.htm.
Could These 3 Biotechs Help Fight the MERS Virus?
Leo Sun, The Motley Fool - Motley Fool - Sat May 17, 5:36PM CDT
MERS (Middle Eastern Respiratory Syndrome) has now spread to 16 countries since first appearing in Saudi Arabia in 2012. MERS causes similar symptoms as SARS (Severe Acute Respiratory Syndrome) -- including a fever, cough, and shortness of breath...
Genital Herpes - Pipeline Review, H1 2014: 8 Companies and 13 Drugs Proifled
M2 - Mon May 12, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mkn245/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Genital Herpes - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Genital Herpes and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Genital Herpes pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Agenus, Inc. - AiCuris GmbH & Co. KG - Flamel Technologies S.A. - Foamix Ltd. - NanoViricides, Inc. - Profectus BioSciences, Inc. - Starpharma Holdings Limited - Vical Incorporated Drug Profiles: - acyclovir SR - HerpV Vaccine - pritelivir - astodrimer - VCLHB-01 - VCLHM-01 - ZEP-3 - HerpeCide-I - HSV-2 Vaccine - acyclovir - Genital Herpes Vaccine - Therapeutic/Prophylactic Vaccine Program For Herpes Simplex Virus - Drugs for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/mk...tal_herpes
3 Under-$10 Stocks Triggering Breakout Trades
at The Street - Wed May 07, 5:00AM CDT
Keep these stocks under $10 on your breakout trading radar.
NanoViricides Reports Novel Drug Candidates for Treatment of the MERS (Middle East Respiratory Syndrome) Corona Virus Ready for Animal Testing
Business Wire - Mon May 05, 6:01AM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company" reported today that it has designed and synthesized novel nanoviricides(R) drug candidates in quantities sufficient for testing in animals infected with the MERS Corona Virus.
NanoViricides, Inc. President Dr. Anil R. Diwan Recognized as "Researcher of the Year" by BusinessNewHaven, a Connecticut Area Business Journal
Business Wire - Mon Mar 31, 7:55AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company" announced today that Anil R. Diwan, Ph.D., President, Chairman, and co-Founder of the Company was recognized as the "2014 Researcher of the Year" by BusinessNewHaven, a business journal, and New Haven Magazine, publications that serve the state of Connecticut.
NanoViricides Reports that its Director Dr. Milton Boniuk, a Director, Has Invested $5M into the Company in a Convertible Debenture
Business Wire - Wed Jul 02, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"
reported today that Milton Boniuk, MD, the Caroline F. Elles Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company, has invested $5M in the Company in the form of a convertible debenture (the "Debenture" . NanoViricides Down 5.4%, Shares Slide into the Red (NNVC)
Comtex SmarTrend(R) - Tue Jul 01, 12:44PM CDT
NanoViricides (NASDAQ:NNVC) is one of today's worst performing low-priced stocks, down 5.4% to $4.00 on 1.0x average daily volume. NanoViricides has traded 262,000 shares thus far today, vs. average volume of 256,000 shares per day. The stock has underperformed the Dow (-5.4% to the Dow's 1.0%) and underperformed the S&P 500 (-5.4% to the S&P's 0.9%) during today's trading.
Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fp7wfj/herpes_labialis) has announced the addition of the "Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beech Tree Labs, Inc. - BioAlliance Pharma SA - Foamix Ltd. - NanoBio Corporation - NanoViricides, Inc. - Redox Pharmaceutical Corporation For more information visit http://www.researchandmarkets.com/research/fp...s_labialis
NanoViricides Reports That a Certificate of Occupancy Has Been Issued for the New cGMP Manufacturing and R&D Facility in Shelton, CT
Business Wire - Wed Jun 25, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"
reports that the Construction Phase for its total renovation program of the facility at 1 Controls Drive, Shelton, CT is now complete. The City of Shelton has issued a Certificate of Occupancy for this facility after inspection of the new facility. NanoViricides is now performing specific modifications for its custom equipment and utilities needs. Simultaneously, the facility validation process has also been started. The Company is in negotiations to purchase this facility rather than to lease it. NanoViricides President Dr. Diwan to Present at the Wall Street Analyst Forum Today, June 19th, in New York City
Business Wire - Thu Jun 19, 7:30AM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
reports that its President, Dr. Anil Diwan, will be presenting at the Wall Street Analyst Forum's 25th Annual Institutional Investor Conference today at 11:20am Eastern Time at the University Club in New York City. The event is being webcast. To participate, the registration link is http://www.visualwebcaster.com/event.asp?id=99581. Investors interested in attending the presentation in person may register at: www.analyst-conference.com/investor-registration. NanoViricides, Inc. Reports That NNVC is in the Preliminary Additions List of The Russell Global, The Russell 3000, The Russell 2000 and the Russell Microcap Indexes
Business Wire - Mon Jun 16, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"
, reports that NanoViricides, Inc. is in the preliminary list for addition to the Russell Global, Russell 3000, Russell 2000, and Russell Microcap Indexes when Russell Investments ("Russell" reconstitutes its U.S. and global equity indexes on June 27, 2014. The preliminary additions and deletions for the Russell Global, Russell 3000(R) and Russell Microcap(R) Indexes were listed on the Russell website on Friday, June 13, 2014, after the U.S. stock market closed (http://www.russell.com/indexes/americas/tools-resources/reconstitution/additions-deletions.page). Russell will provide further updates on Friday, June 20 and 27. The newly reconstituted Russell indexes will take effect after the US stock market close on Friday, June 27. Coronavirus Infection - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3fg3jv/coronavirus) has announced the addition of the "Coronavirus Infection - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronavirus Infection and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Novavax, Inc. - NanoViricides, Inc. - Synairgen plc For more information visit http://www.researchandmarkets.com/research/3f...oronavirus
NanoViricides CEO Dr. Seymour to Present at the LD Micro Invitational Conference Today, June 4th
Business Wire - Wed Jun 04, 6:00AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"
reports that its CEO, Dr. Eugene Seymour, MD, MPH, will be presenting at the LD Micro Invitational Conference today at 5pm Pacific Time at the Luxe Sunset Boulevard Hotel in West Los Angeles. SeeThruEquity 3rd Annual Microcap Investor Conference To Be Held May 28, 2014
ACCESSWIRE - Thu May 22, 8:11AM CDT
Conference Being Held at Convene Grand Central in Midtown
NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Clinical Trials of its First Two Drug Candidates
Business Wire - Mon May 19, 6:01AM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
, has filed its quarterly report with the Securities and Exchange Commission on Thursday, May 15th, in a timely fashion. The submission can be downloaded from the SEC website at http://www.sec.gov/Archives/edgar/data/137900...44_10q.htm. Could These 3 Biotechs Help Fight the MERS Virus?
Leo Sun, The Motley Fool - Motley Fool - Sat May 17, 5:36PM CDT
MERS (Middle Eastern Respiratory Syndrome) has now spread to 16 countries since first appearing in Saudi Arabia in 2012. MERS causes similar symptoms as SARS (Severe Acute Respiratory Syndrome) -- including a fever, cough, and shortness of breath...
Genital Herpes - Pipeline Review, H1 2014: 8 Companies and 13 Drugs Proifled
M2 - Mon May 12, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mkn245/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Genital Herpes - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Genital Herpes and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Genital Herpes pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Agenus, Inc. - AiCuris GmbH & Co. KG - Flamel Technologies S.A. - Foamix Ltd. - NanoViricides, Inc. - Profectus BioSciences, Inc. - Starpharma Holdings Limited - Vical Incorporated Drug Profiles: - acyclovir SR - HerpV Vaccine - pritelivir - astodrimer - VCLHB-01 - VCLHM-01 - ZEP-3 - HerpeCide-I - HSV-2 Vaccine - acyclovir - Genital Herpes Vaccine - Therapeutic/Prophylactic Vaccine Program For Herpes Simplex Virus - Drugs for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/mk...tal_herpes
3 Under-$10 Stocks Triggering Breakout Trades
at The Street - Wed May 07, 5:00AM CDT
Keep these stocks under $10 on your breakout trading radar.
NanoViricides Reports Novel Drug Candidates for Treatment of the MERS (Middle East Respiratory Syndrome) Corona Virus Ready for Animal Testing
Business Wire - Mon May 05, 6:01AM CDT
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"
reported today that it has designed and synthesized novel nanoviricides(R) drug candidates in quantities sufficient for testing in animals infected with the MERS Corona Virus. NanoViricides, Inc. President Dr. Anil R. Diwan Recognized as "Researcher of the Year" by BusinessNewHaven, a Connecticut Area Business Journal
Business Wire - Mon Mar 31, 7:55AM CDT
NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company"
announced today that Anil R. Diwan, Ph.D., President, Chairman, and co-Founder of the Company was recognized as the "2014 Researcher of the Year" by BusinessNewHaven, a business journal, and New Haven Magazine, publications that serve the state of Connecticut. 
(0)
(0)